

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

Claims 1-21 (Canceled).

Claim 22 (Currently Amended). An inhibitor composition of *Helicobacter pylori* colonization, consisting essentially of a glycoprotein which is prepared by contacting a glycoprotein-containing substance from whey of bovine milk or albumen of chicken eggs with *Helicobacter pylori* urease and isolating and purifying the glycoprotein specifically bound to the urease.

Claim 23 (Currently Amended). A pharmaceutical composition for ~~preventing or~~ treating a gastrointestinal disease caused by ~~or associated with~~ *Helicobacter pylori* in mammals, comprising the inhibitor composition according to Claim 22.

Claim 24 (Currently Amended). A food ~~which prevents or treats a gastrointestinal disease caused by or associated with~~ for inhibiting *Helicobacter pylori* colonization in mammals when consumed in an effective amount, comprising the inhibitor composition according to Claim 22.

Claim 25 (Currently Amended). An inhibitor composition of *Helicobacter pylori* colonization, comprising the inhibitor composition according to Claim 22 and an inhibitor of gastric acid secretion.

Claim 26 (Currently Amended). A pharmaceutical composition for ~~preventing or~~ treating a gastrointestinal disease caused by ~~or associated with~~ *Helicobacter pylori* in mammals, comprising the inhibitor composition according to Claim 22 and an inhibitor of gastric acid secretion.

Claim 27 (Allowed). A process for preparing a glycoprotein which specifically binds to urease of *Helicobacter pylori*, comprising contacting a glycoprotein-containing substance with *Helicobacter pylori* urease and isolating and purifying the glycoprotein specifically bound to the urease.

Claim 28 (Allowed). The process according to Claim 27, wherein said contacting step involves affinity chromatography using a column on which the urease is immobilized.

Claim 29 (Allowed). A process for preparing an inhibitor of *Helicobacter pylori* colonization, comprising contacting a glycoprotein-containing substance with *Helicobacter pylori* urease and isolating and purifying the glycoprotein specifically bound to the urease.

Claim 30 (Allowed). The process according to Claim 29, wherein said contacting step involves affinity chromatography using a column on which the urease is immobilized.

Claim 31 (Currently Amended) The inhibitor composition according to Claim 22, wherein said contacting step involves affinity chromatography using a column on which the urease is immobilized.

Claim 32 (Currently Amended). The inhibitor composition according to Claim 22, wherein the urease immobilized on the column is recombinant urease.

Claim 33 (Currently Amended). The inhibitor composition according to Claim 22, wherein the glycoprotein-containing substance is high molecular weight whey concentrate.

Claim 34 (Currently Amended). The inhibitor composition according to Claim 22, wherein the glycoprotein-containing substance is high molecular weight albumen protein concentrate.

Claim 35 (New). A method for inhibiting *Helicobacter pylori* colonization in mammals including humans, comprising orally administering to a mammal a glycoprotein which specifically binds to urease of *Helicobacter pylori* in an effective amount for inhibiting *Helicobacter pylori* colonization, the glycoprotein being obtained by isolation and purification from a glycoprotein-containing substance from whey of bovine milk or

albumen of chicken eggs using a method which utilizes specific adsorption to *Helicobacter pylori*.

Claim 36 (New). A method for inhibiting *Helicobacter pylori* colonization in mammals including humans, comprising orally administering to a mammal a glycoprotein which specifically binds to urease of *Helicobacter pylori* and an inhibitor of gastric acid secretion in an effective amount for inhibiting *Helicobacter pylori* colonization, the glycoprotein being obtained by isolation and purification from a glycoprotein-containing substance from whey of bovine milk or albumen of chicken eggs using a method which utilizes specific adsorption to *Helicobacter pylori* urease.

Claim 37 (New). A method for treating a disease caused by *Helicobacter pylori* in mammals including humans, comprising orally administering to a mammal a glycoprotein which specifically binds to urease of *Helicobacter pylori* in an effective amount for treating the disease so as to inhibit *Helicobacter pylori* colonization, the glycoprotein being obtained by isolation and purification from a glycoprotein-containing substance from whey of bovine milk or albumen of chicken eggs using a method which utilizes specific adsorption to *Helicobacter pylori* urease.

Claim 38 (New). A method for treating a disease caused by *Helicobacter pylori* in mammals including humans, comprising orally administering to a mammal a glycoprotein which specifically binds to urease of *Helicobacter pylori* in an inhibitor of gastric acid

secretion in an effective amount for treating the disease so as to inhibit *Helicobacter pylori* colonization, the glycoprotein being obtained by isolation and purification from a glycoprotein-containing substance from whey of bovine milk or albumen of chicken eggs using a method which utilizes specific adsorption to *Helicobacter pylori* urease